[1] |
HIGASHI T, FRIEDMAN SL, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. DOI: 10.1016/j.addr.2017.05.007.
|
[2] |
FRIEDMAN SL. Molecular mechanisms of hepatic fibrosis and principles of therapy[J]. J Gastroenterol, 1997, 32(3): 424-430. DOI: 10.1007/BF02934504.
|
[3] |
DERYNCK R, BUDI EH. Specificity, versatility, and control of TGF-β family signaling[J]. Sci Signal, 2019, 12(570): eaav5183. DOI: 10.1126/scisignal.aav5183.
|
[4] |
LIU J, KONG D, QIU J, et al. Praziquantel ameliorates CCl4-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cells[J]. Br J Pharmacol, 2019, 176(24): 4666-4680. DOI: 10.1111/bph.14831.
|
[5] |
NI XX, LI XY, WANG Q, et al. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway[J]. J Physiol Biochem, 2021, 77(1): 35-45. DOI: 10.1007/s13105-020-00777-7.
|
[6] |
OGAWA H, KAJI K, NISHIMURA N, et al. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis[J]. J Cell Mol Med, 2021, 25(8): 4001-4013. DOI: 10.1111/jcmm.16363.
|
[7] |
ZHANG W, YANG GY, SHEN DX, et al. Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line -derived neurotrophic factor[J]. J Clin Hepatol, 2021, 37(3): 575-581. DOI: 10.3969/j.issn.1001-5256.2021.03.015.
张玮, 杨广越, 沈东晓, 等. 下瘀血汤抑制胶质细胞源性神经营养因子抗肝纤维化的作用机制[J]. 临床肝胆病杂志, 2021, 37(3): 575-581. DOI: 10.3969/j.issn.1001-5256.2021.03.015.
|
[8] |
CHOI S, JUNG HJ, KIM MW, et al. A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice[J]. Biochem Biophys Res Commun, 2019, 513(1): 49-55. DOI: 10.1016/j.bbrc.2019.03.156.
|
[9] |
LYU L, YIN JK, ZHANG Z, et al. Role of ruxolitinib in the target inhibition of hepatic stellate cell activation and mechanism[J]. J Shanxi Med Univ, 2020, 51(2): 141-146. DOI: 10.13753/j.issn.1007-6611.2020.02.007.
律玲, 阴继凯, 张章, 等. 芦可替尼靶向抑制肝星状细胞活化的作用及机制[J]. 山西医科大学学报, 2020, 51(2): 141-146. DOI: 10.13753/j.issn.1007-6611.2020.02.007.
|
[10] |
SU TH, SHIAU CW, JAO P, et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition[J]. Proc Natl Acad Sci U S A, 2015, 112(23): 7243-7248. DOI: 10.1073/pnas.1507499112.
|
[11] |
DENG YR, MA HD, TSUNEYAMA K, et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib[J]. J Autoimmun, 2013, 46: 25-34. DOI: 10.1016/j.jaut.2013.07.008.
|
[12] |
MARTÍ-RODRIGO A, ALEGRE F, MORAGREGA ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5): 920-932. DOI: 10.1136/gutjnl-2019-318372.
|
[13] |
PERUGORRIA MJ, OLAIZOLA P, LABIANO I, et al. Wnt-β-catenin signalling in liver development, health and disease[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(2): 121-136. DOI: 10.1038/s41575-018-0075-9.
|
[14] |
RAO S, XIANG J, HUANG J, et al. PRC1 promotes GLI1-dependent osteopontin expression in association with the Wnt/β-catenin signaling pathway and aggravates liver fibrosis[J]. Cell Biosci, 2019, 9: 100. DOI: 10.1186/s13578-019-0363-2.
|
[15] |
RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
|
[16] |
ZHANG M, HAUGHEY M, WANG NY, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs[J]. PLoS One, 2020, 15(3): e0229445. DOI: 10.1371/journal.pone.0229445.
|
[17] |
ZHU C, KIM K, WANG X, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis[J]. Sci Transl Med, 2018, 10(468): eaat0344. DOI: 10.1126/scitranslmed.aat0344.
|
[18] |
RICHTER LR, WAN Q, WEN D, et al. Targeted delivery of Notch inhibitor attenuates obesity-induced glucose intolerance and liver fibrosis[J]. ACS Nano, 2020, 14(6): 6878-6886. DOI: 10.1021/acsnano.0c01007.
|
[19] |
ESMAIL MM, SAEED NM, MICHEL HE, et al. The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways[J]. Toxicol Lett, 2021, 347: 23-35. DOI: 10.1016/j.toxlet.2021.04.018.
|
[20] |
DAVEY MG, MCTEIR L, BARRIE AM, et al. Loss of cilia causes embryonic lung hypoplasia, liver fibrosis, and cholestasis in the talpid3 ciliopathy mutant[J]. Organogenesis, 2014, 10(2): 177-185. DOI: 10.4161/org.28819.
|
[21] |
GU S, YAN M, WANG C, et al. Microcystin-leucine-arginine induces liver fibrosis by activating the Hedgehog pathway in hepatic stellate cells[J]. Biochem Biophys Res Commun, 2020, 533(4): 770-778. DOI: 10.1016/j.bbrc.2020.09.075.
|
[22] |
FENG J, WANG C, LIU T, et al. Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis[J]. J Cell Mol Med, 2019, 23(9): 6479-6493. DOI: 10.1111/jcmm.14543.
|
[23] |
SHEN JY, YAN JY, WEI XZ, et al. Gant61 ameliorates CCl4-induced liver fibrosis by inhibition of Hedgehog signaling activity[J]. Toxicol Appl Pharmacol, 2020, 387: 114853. DOI: 10.1016/j.taap.2019.114853.
|
[24] |
FIORUCCI S, ANTONELLI E, RIZZO G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis[J]. Gastroenterology, 2004, 127(5): 1497-1512. DOI: 10.1053/j.gastro.2004.08.001.
|
[25] |
FIORUCCI S, RIZZO G, ANTONELLI E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis[J]. J Pharmacol Exp Ther, 2005, 314(2): 584-595. DOI: 10.1124/jpet.105.084905.
|
[26] |
YOUNOSSI Z M, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7.
|
[27] |
WANG Y, NAKAJIMA T, GONZALEZ FJ, et al. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice[J]. Int J Mol Sci, 2020, 21(6) : 2061. DOI: 10.3390/ijms21062061.
|
[28] |
KLAVDIANOU K, LIOSSIS SN, SAKKAS L, et al. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?[J]. Semin Arthritis Rheum, 2017, 46(4): 430-438. DOI: 10.1016/j.semarthrit.2016.08.014.
|
[29] |
KUMAR DP, CAFFREY R, MARIONEAUX J, et al. The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease[J]. Sci Rep, 2020, 10(1): 9330. DOI: 10.1038/s41598-020-66458-z.
|
[30] |
MARRA F, DEFRANCO R, ROBINO G, et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis[J]. World J Gastroenterol, 2005, 11(32): 4931-4938. DOI: 10.3748/wjg.v11.i32.4931.
|
[31] |
CHEN W, YAN X, YANG A, et al. miRNA-150-5p promotes hepatic stellate cell proliferation and sensitizes hepatocyte apoptosis during liver fibrosis[J]. Epigenomics, 2020, 12(1): 53-67. DOI: 10.2217/epi-2019-0104.
|
肝纤维化相关信号通路及其相应的抗肝纤维化药物研究进展-附录.pdf |